2022 American Transplant Congress » Kidney Immunosuppression: Novel Regimens and Drug Minimization

7:00pm-8:00pm

A Pilot Study Using Registry-Based External Controls for the Cyclosporine Arm of the BENEFIT Study

A. Klein¹, D. Stewart², A. Toll², W. E. Fitzsimmons¹

7:00pm-8:00pm

A Prospective Randomised, Controlled Trial Switching Sirolimus For Mycophenolate To Enhance Immunological Responses To Third Dose Covid-19 Vaccination In Kidney Transplant Recipients With Poor Baseline Humoral Immunity

M. J. Tunbridge¹, G. Perkins², T. Salehi¹, B. Grubor-Bauk³, B. Sim¹, T. Ying⁴, J. J. Singer⁵, S. C. Barry⁶, P. Hissaria⁷, S. Chadban⁸, P. T. Coates¹

7:00pm-8:00pm

Adherence, Outcomes and Adverse Effects in Pediatric Renal Transplant Patients After Early Steroid-Withdrawal and Low-Dose Calcineurin Inhibitor Maintenance Immunosuppression

A. Garcia¹, R. Plews¹, M. Moran¹, F. Trujillo¹, A. Martinez¹, N. Koizumi², D. Conti¹, J. Ortiz¹

7:00pm-8:00pm

Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation

N. Fujiyama¹, M. Saito², R. Yamamoto², R. Sagehashi², T. Saito², Y. Aoyama², K. Numakura², T. Habuchi², S. Satoh¹

7:00pm-8:00pm

Conversion from Immediate to Extended-Release Tacrolimus (LCP-Tac) Six Months After Renal Transplantation Optimizes Safety and Efficacy

S. P. Patel, F. Bartlett, T. Sprague, J. Newman, E. Andrade, N. Rao, N. Patel, D. Dubay, V. Rohan, M. Casey, D. Taber

7:00pm-8:00pm

Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity

K. Hotta, N. Iwahara, T. Tanabe, N. Shinohara

7:00pm-8:00pm

De-Novo Belatacept Therapy is Associated with Higher Levels of BK Viremia and Lower Rates of BK Clearance in Kidney Transplantation Patients

G. Petrossian¹, J. Ortiz², K. Addonizio¹, L. Teixeira¹, A. Hsiao¹, R. James³, N. Koizumi³, S. Patel⁴, D. Conti², R. Plews²

7:00pm-8:00pm

Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients

A. Rizvi¹, M. Kueht², S. Hussain³, J. Fair², R. Ramirez⁴, A. Gamilla-Crudo⁵, M. Mujtaba⁵

7:00pm-8:00pm

Early Experience with 4-drug Maintenance Immunosuppression in Kidney and Pancreas Transplant Recipients

S. Mouawad¹, C. Shoemaker², J. Geyston³, A. Nishio Lucar³

7:00pm-8:00pm

Early Outcomes of Single Dose Eculizumab for Abo-Incompatible Living Donor Renal Transplantation

K. Heagler, M. Campara, P. Di Cocco, S. Gaitonde, I. Tang, J. Almario Alvarez, M. Spaggiari, J. Benken, C. S. Muran, B. Valdepenas, D. Pierce, I. Tzvetanov, E. Benedetti

7:00pm-8:00pm

Effect of Immunosuppression Withdrawal After Graft Failure on Re-Kidney Transplantation Outcomes

J. Ahn¹, S. Sandal², S. Bae¹, D. Segev¹, M. McAdams-DeMarco¹

7:00pm-8:00pm

Evaluating the Risk and Benefit of Once Daily Delayed Release Mycophenolate in Pediatric Kidney Transplant Recipients

L. Maestretti¹, A. McGrath¹, A. Fong¹, A. Brubaker², A. Gallo³, P. Grimm³, A. Chaudhuri³

7:00pm-8:00pm

How Does Anti-CD38 Antibody Treatment (Daratumumab) Impact Immunological Assessment in Solid Organ Transplantation?

S. Ho¹, K. Putnam², C. Peiter², W. Herczyk², J. Gerlach³, E. Campagnaro⁴, Y. Lu⁴, K. Woodside⁴, M. Cusick⁴

7:00pm-8:00pm

Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study

I. Tawhari¹, P. Hallak¹, S. Hartzell², V. Mas³, P. Cravedi², J. Leventhal¹, J. Ansari¹, L. Gallon¹

7:00pm-8:00pm

Improvement in Kidney Function After Early Conversion to Belatacept-Based Regimen in Allografts with Biopsy-Proven Donor Vascular Disease

T. Ommert¹, J. Javier¹, J. Jackson¹, C. Klein²

7:00pm-8:00pm

Kidney Transplant Recipients with Diabetic Mellitus Demand Larger Doses of Mycophenolate Mofetil

D. Takamoto, H. Sasaki, S. Harada, Y. Takada, H. Harada, T. Tsujimoto

7:00pm-8:00pm

Long-Term Effects of Conversion from Calcineurin Inhibitors to Sirolimus for the Recipients with Low Immunological Risk in Renal Allograft

Q. Wu, J. Chen, D. Cheng, X. Ni, X. Li, K. Xie, W. Jiqiu

7:00pm-8:00pm

Meta-Analysis of the Chronic Exposure to Calcineurin Inhibitors and the Risk for Chronic and End-Stage Kidney Disease in Non-Renal Solid Organ Transplant Recipients

A. Alvarez Elias¹, M. Riedl¹, D. Stewart², A. Ruco³, P. Bobos³, S. Maharaj⁴, V. Shah⁵, E. Uleryk⁶, C. Teoh¹, R. Parekh¹

7:00pm-8:00pm

Optimizing Kidney Transplant Immunosuppression Using a Phenotypic Personalized Dosing Model

J. F. Bruner¹, N. Padmanabhan², C. Ho², A. Zarrinpar¹

7:00pm-8:00pm

Outcomes in Elderly Black Renal Transplant Recipients Receiving Basiliximab Induction and Early Steroid Withdrawal

E. Garcia, T. Sparkes, A. Szczepanik, S. Bova, J. Bromberg, A. Haririan, J. Casale

7:00pm-8:00pm

Outcomes of Very Small Pediatric Donor Kidneys Utilizing Belatacept-Based Immunosuppression in Adult Recipients

K. Heinen¹, A. Carlson², A. Chan¹, M. M. Eiting¹, T. Larson¹, B. Sirandas¹, C. Truax¹, L. Smith¹

7:00pm-8:00pm

Outcomes of a Novel Belatacept-Based Regimen – Beyond 2 Years of Follow-Up

G. Katz-Greenberg¹, J. Byrns²

7:00pm-8:00pm

Prevention of the Progression in Chronic Calcineurin Inhibitors Nephrotoxicity via Steroids Anti-Inflammatory Effects

N. Iwahara¹, K. Hotta¹, Y. Tanaka¹, I. Takahashi¹, R. Hasebe¹, H. Okada¹, T. Tsuji², Y. Takada², H. Higuchi², H. Sasaki¹, T. Tanabe¹, D. Iwami³, N. Shinohara¹, M. Murakami¹

7:00pm-8:00pm

Randomized, Phase 4 Study Evaluating the Pharmacokinetics and Tolerability of the New Tacrolimus Tablet Formulation (Tacrobell Tab) in Kidney Transplant Recipients

A. Han¹, E. Cho¹, H. Y. Woo¹, C. Ara¹, H. Lee², Y. Kim³, Y. Park⁴, J. Oh⁴, S. Min¹, J. Ha¹

7:00pm-8:00pm

Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression

B. Sirandas, A. Chan, M. Eiting, T. Larson, C. Truax, L. Smith

7:00pm-8:00pm

Reduced Dose Mycophenolate Does Not Increase the Risk of Rejection Following Renal Transplantation

L. Bowman¹, A. Webb¹, S. Desai², D. Patino³, V. Subramanian⁴, S. Mohammed⁵, M. Gosselin⁶, K. Robichaux⁵, J. Buggs⁴, A. Kumar⁷

7:00pm-8:00pm

The Promise Of Tolerance In Living Donor Kidney Transplant (LDKT): A Retrospective, Real-world Assessment Of The Safety And Efficacy Of LDKT With FCR001 Investigational Cell-therapy Compared With Standard Of Care (SOC)

N. Krieger¹, J. R. Leventhal², B. Ho³, M. Richards⁴, D. Schaumberg⁴, S. Ildstad⁵, D. Axelrod⁶

7:00pm-8:00pm

The Role Of Gut Microbiome In Optimum Dose Selection Of Tacrolimus For Kidney Transplant Recipients

M. Nayebpour¹, N. Koizumi¹, J. Melancon²

7:00pm-8:00pm

The Role of Gut Microbiota in Tacrolimus Blood Level Fluctuation, Time in Therapeutic Range and AlloSure Donor Derived Cell-Free DNA, Controlling for CYP3A5

M. Nayebpour¹, N. Koizumi¹, J. Melancon², M. Hasan²

7:00pm-8:00pm

The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation

E. Siskind¹, J. Splinter¹, C. Taing¹, A. Adekile², S. Njim¹, S. Shah¹, R. Plews³, D. Conti⁴, S. Patel²

7:00pm-8:00pm

Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients

G. Osuchukwu¹, A. Trevino¹, L. Beretich², S. McCormick², N. Kaur², R. White², P. Gauthier²

7:00pm-8:00pm

Use of De Novo mTOR Inhibitors in Highly Sensitized Kidney Transplant Recipients

J. Bastos¹, T. Freesz², C. Bisi³, C. Marinho², A. Pires², V. Colares³, R. Neto², G. Ferreira²

7:00pm-8:00pm

Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus

R. Zhang¹, S. Ge¹, M. Chu¹, J. Kahwaji², A. Karasyov¹, D. Lovato¹, A. Vo², J. Choi², M. Toyoda¹, S. Jordan²

7:00pm-8:00pm

XR Tacrolimus Dosing By Ideal Body Weight Reduces Incidence Of Early Supratherapeutic Tacrolimus Concentrations

G. Codispodo, J. Hedvat, D. Salerno, N. Lange